Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Attentional Bias in Body Dysmorphic Disorder (VAB)

This study has been completed.
Information provided by (Responsible Party):
Sabine Wilhelm, Massachusetts General Hospital Identifier:
First received: July 15, 2011
Last updated: December 2, 2014
Last verified: December 2014
Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.

Body Dysmorphic Disorders

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Attentional Bias in Body Dysmorphic Disorder

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Attention Pattern [ Time Frame: Day 2 ]
    Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.

Secondary Outcome Measures:
  • Subjective Units of Distress Scale (SUDS) [ Time Frame: Day 2 ]
    Participants will provide a distress score based on the facial images observed.

  • Facial Attractiveness [ Time Frame: Day 2 ]
    Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face.

Enrollment: 51
Study Start Date: March 2011
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Body dysmorphic disorder (BDD) Participants
Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
Healthy Controls
Males and females 18 years of age or older with ability to provide informed consent and understand study staff.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study will include 40 participants, consisting of 20 BDD participants and 20 matched healthy controls.

Inclusion Criteria for BDD and healthy control participants:

  • males and females 18 years of age or older
  • sufficient fluency of English to understand study staff, procedures, and questionnaires
  • ability to provide informed consent

Inclusion for BDD participants only;

  • primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD
  • BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20
  • primary facial/head concern

Exclusion Criteria:

  • Major medical or neurological conditions
  • schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD
  • current suicidality
  • current homicidality

Exclusion criteria for healthy controls:

  • Any current Axis I psychiatric illness
  • history of BDD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01398904

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Sabine Wilhelm, Ph. D. Massachusetts General Hospital
Study Director: Jennifer Greenberg, Psy. D. Massachusetts General Hospital
  More Information


Responsible Party: Sabine Wilhelm, Director, OCD & Related Disorders Program, Massachusetts General Hospital Identifier: NCT01398904     History of Changes
Other Study ID Numbers: 2010P002912
Study First Received: July 15, 2011
Last Updated: December 2, 2014

Keywords provided by Massachusetts General Hospital:

Additional relevant MeSH terms:
Body Dysmorphic Disorders
Pathologic Processes
Somatoform Disorders
Mental Disorders processed this record on April 28, 2017